Benefits and risks of fetal red-cell transfusion after 32 weeks gestation

Eur J Obstet Gynecol Reprod Biol. 2000 Sep;92(1):91-6. doi: 10.1016/s0301-2115(00)00430-9.

Abstract

Objective: To compare the outcome after intrauterine transfusion (IUT) between fetuses treated before and those treated after 32 weeks gestation.

Setting: National referral center for intrauterine treatment of red-cell alloimmunization in The Netherlands.

Study design: Retrospective evaluation of an 11 year period, during which 209 fetuses were treated for alloimmune hemolytic disease with 609 red-cell IUTs. We compared fetal and neonatal outcome in three groups: fetuses only treated before 32 weeks gestation (group A, n=46), those treated both before and after 32 weeks (group B, n=117), and those where IUT was started at or after 32 weeks (group C, n=46).

Results: Survival rate was 48% in group A, 100% in group B, and 91% in group C. Moreover, fetuses in group A were hydropic significantly more often. Short-term perinatal loss rate after IUT was 3.4% in the 409 procedures performed before 32 weeks and 1.0% in the 200 procedures performed after 32 weeks gestation.

Conclusion: Perinatal losses were much more common in fetuses only treated before 32 weeks gestation. Two procedure-related perinatal losses in 200 IUT after 32 weeks remain a matter of concern because of the good prospects of alternative extrauterine treatment.

Publication types

  • Case Reports
  • Comparative Study
  • Evaluation Study

MeSH terms

  • Blood Transfusion, Intrauterine* / adverse effects
  • Cesarean Section
  • Erythroblastosis, Fetal / mortality
  • Erythroblastosis, Fetal / therapy*
  • Female
  • Fetal Death
  • Gestational Age
  • Humans
  • Infant Mortality
  • Infant, Newborn
  • Pregnancy
  • Pregnancy Trimester, Third
  • Retrospective Studies
  • Rh Isoimmunization / therapy*
  • Risk Factors
  • Treatment Outcome